Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection.
Zheng Wang, Brandilyn A Peters, MacKenzie Bryant...
https://pubmed.ncbi.nlm.nih.gov/37237391/Actively Recruiting
Led by Albert Einstein College of Medicine · Updated on 2026-05-26
40
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying adults with lactase non-persistence LNP, a genetic condition that causes lactose intolerance due to low lactase enzyme levels. This trial aims to evaluate the effects of drinking lactose-containing versus lactose-free milk on gut bacteria and blood sugar control in people with pre-diabetes who normally consume at least one cup of milk daily. The study is based on findings suggesting milk intake may reduce type 2 diabetes risk in LNP individuals by altering gut microbiota and related metabolites. The study begins with a 2-week milk washout period, after which participants are randomly assigned to drink either lactose-containing 1% or 2% or lactose-free 1% or 2% milk for 12 weeks. Milk intake increases in stages half a cup daily for weeks 1-4, one cup daily for weeks 5-8, then two cups daily for weeks 9-12. After the main study period, participants continue drinking two cups daily for an additional two weeks. Participants will have visits before and after the 12-week milk intervention, with tests including lactose challenge hydrogen breath tests and blood draws for glucose, hemoglobin A1c, and metabolomics. Stool samples and continuous glucose monitoring data will be collected at home. The study will assess changes in gastrointestinal symptoms, gut microbiome characteristics, and various measures of blood sugar control throughout the 12 to 14 weeks of participation.
CONDITIONS
Milk for Diabetes Prevention
B
Brandilyn Peters-Samuelson, PhD
Q
Qibin Qi, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Albert Einstein College of Medicine
Lead Sponsor
National Dairy Council
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Lactose-Containing Milk | Lactose-Free Milk |
|---|---|---|
| What it is | Participants drink increasing amounts of regular (lactose-containing) milk over 12 weeks, with specific dosing steps from ½ cup to 2 cups per day. This approach provides both lactose and dairy nutrients. | Participants drink increasing amounts of lactose-free milk, following the same dosing schedule as the other arm. This milk contains the same nutrients as standard milk but without lactose. |
| Role in trial | Investigational intervention arm, assessing regular milk’s effect on GI symptoms, gut bacteria, and glycemic outcomes in genetically lactose-intolerant adults with prediabetes. | Active comparator arm, evaluating lactose-free milk (minus lactose) with otherwise matched dairy exposure for comparison of outcomes. |
| Primary use | Evaluated to see if daily lactose-containing milk can be safely incorporated into the diet of lactose non-persistent adults with prediabetes, with attention to digestive symptoms, gut microbiome changes, and glucose control. | Functions as a comparator to determine if removing lactose avoids gastrointestinal symptoms or metabolic effects in a similar nutritional context. |
| How it’s given | Consumed as regular (1% or 2%) milk, starting from ½ cup daily and increasing to 2 cups daily by week 9, continued for 12 weeks, then maintained for 2 weeks after the main study period. | Consumed as lactose-free (1% or 2%) milk following identical increasing dosing and duration steps as the other group. |
| Evidence status | The effect of lactose-containing milk on gut microbiota, gastrointestinal symptoms, and glycemic outcomes in this population is not yet established and is being evaluated in this trial. Some evidence shows that milk intake and lactase gene variation affect type 2 diabetes risk and gut health, but results are mixed and depend on population genetics. | The impact of lactose-free milk in this group is also being determined. Evidence supports that avoiding lactose in lactose non-persistent individuals may reduce gastrointestinal symptoms, but effects on metabolism and microbiome are less clear. |
| Important limitations | Potential for digestive discomfort (such as bloating or gas) in those with the LCT GG genotype. Trial population is limited to adults with prediabetes and low prior milk intake; findings may not apply to all adults with lactose intolerance or to those without prediabetes. Long-term metabolic impact and generalizability remain to be established. | Removes lactose exposure, so findings may not generalize to situations where lactose consumption is desired or unavoidable. Other nutritional elements (such as calcium, protein, and fat) are similar between trial milks. Effects on the gut microbiome and metabolism with chronic use are still being defined. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 weeks
Participants stop consuming milk for 2 weeks before starting the intervention.
No visits; at-home adherence
Duration - 12 weeks
Participants drink lactose-containing or lactose-free milk daily with increasing amounts over 12 weeks.
Visits before and after treatment for tests; daily at-home sample collection and monitoring
Duration - 2 weeks
Participants continue drinking 2 cups of milk daily for 2 weeks after treatment while monitoring continues.
Ongoing continuous glucose monitoring and daily symptom tracking; 1 follow-up visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Zheng Wang, Brandilyn A Peters, MacKenzie Bryant...
https://pubmed.ncbi.nlm.nih.gov/37237391/Jun Chen, Kyle Bittinger, Emily S Charlson...
https://pubmed.ncbi.nlm.nih.gov/22711789/Lisa M Lavange, William D Kalsbeek, Paul D Sorlie...
https://pubmed.ncbi.nlm.nih.gov/20609344/Augusto Anguita-Ruiz, Concepción M Aguilera, Ángel Gil
https://pubmed.ncbi.nlm.nih.gov/32899182/Snigdha Guha, Kaustav Majumder
https://pubmed.ncbi.nlm.nih.gov/35727887/A Carroccio, G Montalto, G Cavera...
https://pubmed.ncbi.nlm.nih.gov/9853544/Jon G Sanders, Sergey Nurk, Rodolfo A Salido...
https://pubmed.ncbi.nlm.nih.gov/31672156/Emily D Parker, Janice Lin, Troy Mahoney...
https://pubmed.ncbi.nlm.nih.gov/37909353/Lonneke JanssenDuijghuijsen, Ellen Looijesteijn, Maartje van den Belt...
https://pubmed.ncbi.nlm.nih.gov/38159728/Ron Caspi, Richard Billington, Ingrid M Keseler...
https://pubmed.ncbi.nlm.nih.gov/31586394/Albert Einstein College of Medicine
Lead Sponsor
National Dairy Council
Collaborating Sponsor